Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
Withdrawn before enrolling · Phase 1
Conditions studied: Pancreatic Cancer
In brief
The purposes of this study are to: * Evaluate the safety and toxicity of tolfenamic acid when used with gemcitabine and radiation therapy in patients with locally advanced or metastatic pancreatic cancer. * Determine the maximum-tolerated dose (MTD) of tolfenamic acid when used with gemcitabine and radiation in pancreatic cancer. * Characterize the pharmacokinetic profile of tolfenamic acid when used with gemcitabine and radiation. * Assess the anti-tumor response to tolfenamic acid when used with gemcitabine and radiation in patients with advanced pancreatic malignancies.
Key facts
- Study ID
- NCT02159248
- Run by
- Orlando Health, Inc.
- People needed
- 0
- Starts
- 2014-03-01
- Expected to finish
- 2019-12-01
- Last updated by the study team
- 2015-04-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UF Health Cancer Center at Orlando Health — Orlando, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.